Home :: Project :: Products

The company is setting set up manufacturing facilities for an aggregate installed capacity of 342 kgs p.a bulk active pharmaceutical ingredients of high value biopharmaceuticals.

In the first phase, SBIL would manufacture Daunomycin, Hyaluronic acid (Pharma grade), Tacrolimus and Rapamycin. Subsequently, a number of products like Cyclosporin A, Probiotics, Lysergic acid, Mycophenolic acid, Clavulenic acid, Vancomycin, Co-enzyme Q10, Interferon β, and monoclonal antibodies (anti-cancer) will be introduced in phases.